stockrowPerspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.
- Revenue
- −72.1%
- EPS
- +24.1%
- Free cash flow
- −66.1%
- Total debt
- −3.57%
Quarter to June 2026, against a year earlier
Follow CATX
Alert me
Perspective Therapeutics, Inc. (CATX) EV/Sales
As of 5 November 2026, Perspective Therapeutics, Inc. (CATX) trades at a EV/Sales of −339×. Over the past ten years it has ranged from −339× (November 2026) to 522× (September 2024) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 67.7× | — |
| FY2024 | −13.6× | — |
| FY2023 | 69.6× | — |
| FY2022 | −1.1× | — |
| FY2021 | 76.1× | 96.92% |
| FY2020 | 38.7× | 4.90% |
| FY2019 | 36.9× | (8.14%) |
| FY2018 | 40.1× | (43.48%) |
| FY2017 | 71.0× | (27.75%) |
| FY2016 | 98.2× | (43.27%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 431× | 63.58% |
| Mar 2026 | 263× | 288.95% |
| Dec 2025 | 67.7× | (11.59%) |
| Sep 2025 | 76.5× | 44.57% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CATX Perspective Therapeutics, Inc. | −339× |
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. compare | 0.3× |
| LUNG Pulmonx Corporation compare | 1.1× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| HYPR Hyperfine, Inc. compare | 2.3× |
| APYX Apyx Medical Corporation compare | 2.5× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| SERA Sera Prognostics, Inc. compare | 641× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)